This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

This study has been terminated.
MacuSight, Inc.
Information provided by (Responsible Party):
Santen Inc. Identifier:
First received: July 8, 2008
Last updated: January 8, 2013
Last verified: July 2010
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.

Condition Intervention Phase
Age-related Macular Degeneration Choroidal Neovascularization Drug: Sirolimus Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by Santen Inc.:

Primary Outcome Measures:
  • Best-corrected visual acuity by ETDRS [ Time Frame: 180 days ]

Secondary Outcome Measures:
  • Best-corrected visual acuity by ETDRS [ Time Frame: 60 days, 120 days ]
  • Safety across injection routes [ Time Frame: Through 1 year ]

Enrollment: 20
Study Start Date: September 2008
Study Completion Date: March 2010
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Sirolimus
Three subconjunctival injections of 1320 micrograms sirolimus each.
Other Name: MS-R002, rapamycin
Experimental: 2 Drug: Sirolimus
Three intravitreal injections of 352 micrograms sirolimus each.
Other Name: MS-R001, rapamycin


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria include, but are not limited to:

  • Diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration
  • Visual acuity of 20/50 to 20/200 in study eye

Exclusion Criteria:

  • Any other ocular disease that could compromise vision in the study eye
  • History of any prior treatment for choroidal neovascularization in the study eye
  • Presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00712491

United States, Arizona
Retinal Consultants of Arizona
Phoenix, Arizona, United States, 85044
Sponsors and Collaborators
Santen Inc.
MacuSight, Inc.
Study Director: Joel Naor, MD MacuSight, Inc.
  More Information

Responsible Party: Santen Inc. Identifier: NCT00712491     History of Changes
Other Study ID Numbers: AMD-002
Study First Received: July 8, 2008
Last Updated: January 8, 2013

Keywords provided by Santen Inc.:
wet AMD

Additional relevant MeSH terms:
Macular Degeneration
Neovascularization, Pathologic
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pathologic Processes
Choroid Diseases
Uveal Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 18, 2017